Fulminant Hepatic Failure Secondary to Erlotinib

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 8, 2007, Pages 917-920

  Liu, Weitian ^a   Makrauer, Frederick L ^a   Qamar, Amir A ^a   Jänne, Pasi A ^a   Odze, Robert D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; ERLOTINIB; FLUNISOLIDE; LANOLIN ALCOHOL; PIMECROLIMUS; PREDNISONE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG WITHDRAWAL; DYSPNEA; FACE RASH; FEMALE; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER FAILURE; LUNG NON SMALL CELL CANCER; RISK FACTOR; SYMPTOM;

ADMINISTRATION, ORAL; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER NEOPLASMS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34547188589     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.04.014     Document Type: Article

References (24)

1. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
2. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107 (2006) 1207-1218
3. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
4. Goodin S. Erlotinib: optimizing therapy with predictors of response?. Clin Cancer Res 12 (2006) 2961-2963
5. Lenz H.J. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 20 Suppl 2 (2006) 5-13
6. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 (2001) 3267-3279
7. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
8. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
9. Polson J., Lee W.M., and American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 41 (2005) 1179-1197
10. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
11. Rajvanshi P., Kowdley K.V., Hirota W.K., et al. Fulminant hepatic failure secondary to neoplastic infiltration of the liver. Clin Gastroenterol 39 (2005) 339-343
12. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N Engl J Med 354 (2006) 731-739
13. Jaeschke H., Gores G.J., Cederbaum A.I., et al. Mechanisms of hepatotoxicity. Toxicol Sci 65 (2002) 166-176
14. Fromenty B., and Pessayre D. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67 (1995) 101-154
15. Lu J.F., Eppler S.M., Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80 (2006) 136-145
16. Hidalgo M., and Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 30 Suppl 7 (2003) 25-33
17. Cohen M.H., Williams G.A., Sridhara R., et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8 (2003) 303-306
18. Ho C., Davis J., Anderson F., et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23 (2005) 8531-8533
19. Seki N., Uematsu K., Shibakuki R., et al. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 24 (2006) 3213-3214
20. Agero A.L., Dusza S.W., Benvenuto-Andrade C., et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55 (2006) 657-670
21. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005) 5235-5246
22. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 38 Suppl 2 (2004) S44-S48
23. Lee W.M., and Senior J.R. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 33 (2005) 155-164
24. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 349 (2003) 474-485